Form 4: ADMA Biologics CEO Adam Grossman Reports Stock Transaction
SEC Form 4 Filing
Adam Grossman, President and CEO of ADMA Biologics, reports disposition of shares to cover tax obligations upon vesting of restricted stock units.
Summary
- On February 25, 2024, Adam S. Grossman, the President and CEO of ADMA Biologics, engaged in a transaction involving the disposition of 22,457 shares of common stock to cover tax obligations.
- The shares were disposed of at a price of $5.26 per share.
- Following the transaction, Grossman directly owns 2,208,853 shares of ADMA Biologics common stock.
- Grossman also indirectly owns 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The transaction may have a minor impact on shareholders due to the change in ownership, but it is unlikely to be significant given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 02/25/2024 | Date of stock transaction (disposition of shares). |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.